Review



4sm xmu-mp-1  (ApexBio)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    ApexBio 4sm xmu-mp-1
    a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, <t>FPH2</t> and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with 4SM from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)
    4sm Xmu Mp 1, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/4sm+xmu-mp-1/4sm+xmu+mp+1/pmc06086841-202-11-5
    Average 90 stars, based on 1 article reviews
    4sm xmu-mp-1 - by Bioz Stars, 2026-08
    90/100 stars

    Images

    1) Product Images from "Optimized HepaRG is a suitable cell source to generate the human liver chimeric mouse model for the chronic hepatitis B virus infection"

    Article Title: Optimized HepaRG is a suitable cell source to generate the human liver chimeric mouse model for the chronic hepatitis B virus infection

    Journal: Emerging Microbes & Infections

    doi: 10.1038/s41426-018-0143-9

    a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, FPH2 and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with 4SM from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)
    Figure Legend Snippet: a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, FPH2 and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with 4SM from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)

    Techniques Used:



    Similar Products

    4sm xmu-mp-1  (ApexBio)
    90
    ApexBio 4sm xmu-mp-1
    a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, <t>FPH2</t> and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with 4SM from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)
    4sm Xmu Mp 1, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/4sm+xmu-mp-1/4sm+xmu+mp+1/pmc06086841-202-11-5
    Average 90 stars, based on 1 article reviews
    4sm xmu-mp-1 - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, FPH2 and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with 4SM from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)

    Journal: Emerging Microbes & Infections

    Article Title: Optimized HepaRG is a suitable cell source to generate the human liver chimeric mouse model for the chronic hepatitis B virus infection

    doi: 10.1038/s41426-018-0143-9

    Figure Lengend Snippet: a Measurements of hALB in the supernatant of the culture medium and cell proliferation capacity of HepaRG cells with the FH1, FPH1, FPH2 and XMU-MP-1 treatment in the one-minus treatment pattern ( n = 4/group) for 1 (left panel) or 2 weeks (right panel). b FACS analysis for the hALB-positive rate of HepaRG cells treated or untreated with 4SM from weeks 0 to 4 in the hepatic differentiation procedure ( n = 4/group). c FACS analysis of the hALB and hAAT double-positive (DP) rate of cells using the hepatic differentiation procedure that was optimized by 4SM treatment and cell enrichment; udHepaRG and cdHepaRG cells were used as controls. d Representative FACS plot for developing DP cells using the 4SM-enhanced hepatic differentiation procedure with or without cell enrichment. (* P < 0.01; **** P < 0.00001; NS no significant difference, U.D. undetectable)

    Article Snippet: The 4SM was purchased from APExBIO, USA (FH1, B3700; FPH1, B3701; FPH2, B4753; XMU-MP-1, A8735).

    Techniques: